| Date | Title | Description |
| 20.05.2025 | Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis | NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase... |
| 20.05.2025 | Philikos kondigt de start aan van een klinische fase 1/2-studie met T-Guard® bij patiënten met systemische sclerose | NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., een Nederlands biotechnologiebedrijf dat op antilichamen gebaseerde therapieën ontwikkelt voor de behandeling van ernstige immuunziekten, heeft vandaag aangekondigd ... |
| 07.05.2025 | InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update | Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company... |
| 01.04.2025 | Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety | HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management systemhygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score = 0+1A)Full results w... |
| 24.03.2025 | Advanced Medical Balloons announces its new hygh-tec Odor Solution™ product, broadening its catheter portfolio | hygh-tec Odor Solution™ will be launched in Q2 2025FDA clearance and MDR certification already securedFirst generation hygh-tec™ catheter rapidly achieved more than a third of the market share in Germany, and addressing a US$ 600+ million m... |
| 20.03.2025 | InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones | Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosu... |
| 07.03.2025 | InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters descr... |
| 07.03.2025 | InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters descr... |
| 28.02.2025 | InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, feat... |
| 20.02.2025 | EG 427 Secures €27 Million to Revolutionize Neurology Treatments | In a significant leap for biotechnology, Paris-based startup EG 427 has successfully closed a €27 million Series B financing round. This funding, co-led by Andera Partners and Bpifrance, marks a pivotal moment for the company as it aims to ... |
| 20.02.2025 | EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development | Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this round Proceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Open... |
| 20.02.2025 | EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development | Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this roundProceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Opens... |
| 06.02.2025 | CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme | A significant step towards the payment to CARBIOS of grant subsidies validated by ADEME and the Grand Est Region, totalling €42.5m, for the construction of the CARBIOS Longlaville biorecycling plant in FranceCARBIOS has reaffirmed its objec... |
| 30.01.2025 | Rentschler Biopharma announces strategic realignment of its global business operations | LAUPHEIM, Germany, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operation... |
| 30.01.2025 | Rentschler Biopharma announces strategic realignment of its global business operations | LAUPHEIM, Germany, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operation... |
| 28.01.2025 | In line with its press release dated 19 December 2024, which mentions the reduction of operating costs and prudent management of its strong cash position, CARBIOS today launched a project to reorganiz... | This project concerns CARBIOS and its subsidiary CARBIOS 54 and could result in the elimination of around 40% of positions.
CARBIOS reaffirms its objective to build its PET biorecycling plant in Longlaville after having secured additional f... |
| 15.01.2025 | InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has grant... |
| 14.01.2025 | Report on Carbios’ liquidity contract with Natixis ODDO BHF | Shares concerned: Carbios (ISIN code: FR0011648716)
Market concerned: Euronext Growth Paris
Clermont-Ferrand (France), 14 January 2025 (6:00 pm CET). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrializatio... |
| 08.01.2025 | ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial | VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis pigmentosaFDA Rare Pediatric Disease Designation... |
| 23.12.2024 | Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD | Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular degenerationTrial planned to enroll 110 patients in the US, Europe, and IsraelStudy design discussed ... |
| 20.12.2024 | InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 | JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in it... |
| 19.12.2024 | Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months | Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months
CARBIOS maintains a robust available cash position of 112 million euros on 30 November 2024
CA... |
| 15.11.2024 | InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products f... |
| 08.11.2024 | InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update | Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025InflaRx pipeline highlighted a... |
| 31.10.2024 | InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference | JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third q... |
| 29.10.2024 | CARBIOS und das Textilkonsortium der Markenhersteller On, Patagonia, PUMA, PVH Corp. und Salomon stellen das weltweit erste zu 100 % biologisch von Faser-zu-Faser-recycelte Kleidungsstück vor | Zum ersten Mal wurde ein Kleidungsstück vollständig aus Textilabfällen hergestellt – nicht aus Flaschen, Verpackungen oder aus neuem Plastik, sondern aus 100 % biologisch recycelten Fasern. Durch die weitere Entwicklung und Industrialisieru... |
| 29.10.2024 | The world’s first 100% “fiber-to-fiber” biorecycled clothing unveiled by multi-brand consortium: CARBIOS, On, Patagonia, PUMA, PVH Corp. and Salomon | For the first time, a piece of clothing is made entirely from textile waste – no bottles, no packaging, no virgin plastic. 100% biorecycled fibers. By developing and industrializing CARBIOS’ enzymatic depolymerization technology to achieve ... |
| 29.10.2024 | The world’s first 100% “fiber-to-fiber” biorecycled clothing unveiled by multi-brand consortium: CARBIOS, On, Patagonia, PUMA, PVH Corp. and Salomon | For the first time, a piece of clothing is made entirely from textile waste – no bottles, no packaging, no virgin plastic. 100% biorecycled fibers.By developing and industrializing CARBIOS’ enzymatic depolymerization technology to achieve 1... |
| 02.10.2024 | CARBIOS announces half-year 2024 financial results and presents its industrial and commercial progress | Construction progress of world’s first PET enzymatic biorecycling plant in France: in line with production targets in 2026Commercial development: several Letters of Intent signed in view of licensing agreements
Consolidated cash position of... |
| 25.09.2024 | SLEEVER® and CARBIOS globally launch world’s first Home Compost biodegradable tamper evident seal: SEELCAP® ONEGO | The SEELCAP® ONEGO innovation is the fruit of a long-term partnership between SLEEVER® and CARBIOS that combines their expertise to produce more environmentally friendly packaging securitySEELCAP® ONEGO will be presented on the SLEEVER (RF1... |
| 25.09.2024 | InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress | JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc an... |
| 24.09.2024 | CARBIOS and Selenis announce strategic partnership to produce PETG issued from CARBIOS’ biorecycling technology for Cosmetic and Healthcare markets | Clermont-Ferrand (France), Tuesday 24 September 2024 (6pm CEST). - CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, a... |
| 19.09.2024 | CARBIOS and SLEEVER® partner up to co-develop and bring to market first Home Compost biodegradable shrinksleeve labels | Clermont-Ferrand and Morangis (France), Thursday 19 September 2024 (6pm CEST). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and... |
| 19.09.2024 | CARBIOS and SLEEVER® partner up to co-develop and bring to market first Home Compost biodegradable shrinksleeve labels | Clermont-Ferrand and Morangis (France), Thursday 19 September 2024 (6pm CEST). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and... |
| 19.09.2024 | CARBIOS und SLEEVER® schließen Partnerschaft zur Entwicklung und Vermarktung der ersten im Heimkompost biologisch abbaubaren Etikettenhüllen | Clermont-Ferrand (Frankreich), Donnerstag, 19. September (18:00 Uhr MESZ). CARBIOS (Euronext Growth Paris: ALCRB), ein Pionier in der Entwicklung und Industrialisierung enzymatischer Lösungen für das Recycling von Kunststoff- und Textilpoly... |
| 03.09.2024 | CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide | Clermont-Ferrand (France), 3 September 2024 (06:45 CET). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces th... |
| 03.09.2024 | InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases | JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for t... |
| 29.08.2024 | Advanced Medical Balloons appoints top-performing US life-science executive to drive business growth | German highly innovative med-tech Advanced Medical Balloons (AMB) has named Stephen K.E. Forden as USA General Manager to expand market presence and build strategic partnerships.Lead product hygh-tec® quickly gained 30% share against market... |
| 29.08.2024 | Advanced Medical Balloons appoints top-performing US life-science executive to drive business growth | German highly innovative med-tech Advanced Medical Balloons (AMB) has named Stephen K.E. Forden as USA General Manager to expand market presence and build strategic partnerships. Lead product hygh-tec® quickly gained 30% share against marke... |
| 27.08.2024 | InflaRx Announces Participation in September Investor Events | JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor... |
| 08.08.2024 | InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update | Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)
Initiation of a Phase 2a study with INF904 in chroni... |
| 06.08.2024 | leon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulation | MUNICH, Aug. 06, 2024 (GLOBE NEWSWIRE) -- leon-nanodrugs GmbH (LEON), a pharmatech company specializing in the development of nanoencapsulation systems for genetic material and other active substances, announced today the closing of a Serie... |
| 06.08.2024 | CARBIOS and FCC Environment announce joint project to establish UK-based PET biorecycling facility using CARBIOS’ licensed technology | Clermont-Ferrand (France) and Doncaster, England (UK), Tuesday 6 August 2024 (06.45 CEST). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of... |
| 01.08.2024 | InflaRx to Report Second Quarter 2024 Results on August 8, 2024 | JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2... |
| 01.08.2024 | CARBIOS and SASA enter discussions for license of 100k ton/year PET biorecycling facility in Turkey | Clermont-Ferrand (France) and Adana (Turkey), Thursday 1 August 2024 (6pm CEST). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic a... |
| 30.07.2024 | InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases | JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it will present preclinical data on the com... |
| 27.06.2024 | CARBIOS and Zhink Group enter official discussions for long-term partnership to build PET biorecycling industrial capacities in China in view of first licensing agreement for 50k tons per year | This partnership would allow Zhink Group to meet its leadership ambitions through increased recycled PET capacities and sustainable competitiveness by offering recycled PET from enzymatic recyclingThis agreement confirms strong traction for... |
| 27.06.2024 | CARBIOS und die ZHINK Gruppe nehmen erste offizielle Gespräche über eine langfristige Partnerschaft zum Aufbau von PET-Biorecycling-Industriekapazitäten in China und eine Lizenzvereinbarung über 50.00... | Die Partnerschaft würde der ZHINK Gruppe erhöhte PET-Recycling-Kapazitäten und eine mittels des Angebots enzymatisch recycelten PETs nachhaltige Wettbewerbsfähigkeit ermöglichen, die den Führungsambitionen des Unternehmens gerecht werden. D... |
| 27.06.2024 | CARBIOS and Zhink Group enter official discussions for long-term partnership to build PET biorecycling industrial capacities in China in view of first licensing agreement for 50k tons per year | This partnership would allow Zhink Group to meet its leadership ambitions through increased recycled PET capacities and sustainable competitiveness by offering recycled PET from enzymatic recycling This agreement confirms strong traction fo... |
| 27.06.2024 | CARBIOS et Zhink Group entament des discussions officielles en vue d'un partenariat à long terme visant à installer des capacités industrielles de biorecyclage du PET en Chine, dans la perspective d'u... | En proposant du PET recyclé issu du recyclage enzymatique, ce partenariat permettrait au groupe Zhink de réaliser ses ambitions de leader en augmentant ses capacités de production de PET recyclé ainsi que sa compétitivité en matière de déve... |
| 24.06.2024 | InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been sele... |
| 18.06.2024 | CARBIOS and TOMRA Textiles join forces to scale circularity of polyester textiles | CARBIOS and TOMRA Textiles will collaborate to close the textiles circularity gap between collection of textile waste and innovative technologies for textile-to-textile recycling
Oslo/Clermont-Ferrand, Tuesday 18 June 2024 (6.45am CEST): CA... |
| 30.05.2024 | L’OCCITANE en Provence et CARBIOS présentent un flacon en PET issu du recyclage enzymatique, fruit d’une filière européenne d’économie circulaire | L’OCCITANE en Provence et CARBIOS présentent un flacon en PET issu du recyclage enzymatique, fruit d’une filière européenne d’économie circulaire CARBIOS, L’OCCITANE en Provence et Pinard Beauty Pack s’unissent pour la mise en mouvement d’u... |
| 30.05.2024 | L'OCCITANE en Provence und CARBIOS präsentieren Kunststoffflakon aus enzymatisch recyceltem PET - das Ergebnis einer europäischen Kooperation für eine Kreislaufwirtschaft | L'OCCITANE en Provence und CARBIOS präsentieren Kunststoffflakon aus enzymatisch recyceltem PET - das Ergebnis einer europäischen Kooperation für eine Kreislaufwirtschaft CARBIOS, L'OCCITANE en Provence und Pinard Beauty Pack schließen sich... |
| 30.05.2024 | L’OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic recycling, the result of a European circular economy | L’OCCITANE en Provence and CARBIOS present a PET bottle made from enzymatic recycling, the result of a European circular economy CARBIOS, L’OCCITANE en Provence and Pinard Beauty Pack join forces to establish an efficient European value cha... |
| 02.05.2024 | CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant | CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant
From end 2026, Hündgen will supply 15kt/year of post-consumer PET flakes to CARBIOS’ first commercial plant
Clermont-Ferrand, France, Thursday 2 May 2024 (0... |
| 02.05.2024 | CARBIOS und Hündgen schließen Liefervereinbarung für die weltweit erste PET-Biorecycling-Anlage | CARBIOS und Hündgen schließen Liefervereinbarung für die weltweit erste PET-Biorecycling-Anlage Ab Ende 2026 wird Hündgen die erste kommerzielle Anlage von CARBIOS mit jährlich 15.000 Tonnen an Post-Consumer-PET-Flakes beliefern
Clermont-Fe... |
| 02.05.2024 | CARBIOS et Hündgen concluent un accord d’approvisionnement pour la première usine de biorecyclage du PET au monde | CARBIOS et Hündgen concluent un accord d’approvisionnement pour la première usine de biorecyclage du PET au monde A partir de fin 2026, Hündgen fournira 15kt/an de paillettes de PET post-consommation à la première usine commerciale de CARBI... |
| 26.04.2024 | CARBIOS 公司攜手合作夥伴為世界首家 PET 塑膠生物降解回收工廠奠基 | CARBIOS 公司攜手合作夥伴為世界首家 PET 塑膠生物降解回收工廠奠基 CARBIOS 公司的這家工廠也是世界首家採用革命性酵素解聚技術降解廢棄塑料的工廠，這標誌著塑料和紡織品向循環經濟轉型邁出的重要一步。
超過 200 名各界嘉賓出席了這一重要儀式，其中包括來自各類機構、合作品牌和行業合作夥伴的代表。
工廠建成後在全力運轉的情況下預計每年可處理 50000 噸預加工的塑料廢物。
隆拉維爾（Longlaville，法國），2024年4月25日（歐洲中部時間19點30分）... |
| 26.04.2024 | CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners | CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS’ first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the ... |
| 26.04.2024 | CARBIOS公司携手合作伙伴为世界首家PET塑料生物降解回收工厂奠基 | CARBIOS公司携手合作伙伴为世界首家PET塑料生物降解回收工厂奠基 CARBIOS公司的这家工厂也是世界首家采用革命性酶解聚技术降解废弃塑料的工厂，这标志着塑料和纺织品向循环经济转型迈出的重要一步。
超过200名各界嘉宾出席了这一重要仪式，其中包括来自各类机构、合作品牌和行业合作伙伴的代表
工厂建成后在全力运转的情况下预计每年可处理50000吨预加工的塑料废物
隆拉维尔（Longlaville，法国），2024年4月25日（欧洲中部时间19点30分）。CARBIOS公司（... |
| 29.02.2024 | CARBIOS und Landbell Group fördern die Kreislauffähigkeit von PET-Abfällen durch die erste biologische Recyclinganlage | CARBIOS und Landbell Group fördern die Kreislauffähigkeit von PET-Abfällen durch die erste biologische Recyclinganlage CARBIOS und Landbell Group unterzeichnen eine Vereinbarung zur Entwicklung und Umsetzung von Lösungen für die Sortierung,... |
| 29.02.2024 | CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant | CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant CARBIOS and Landbell Group sign agreement to develop and implement solutions for the sorting, preparation and enzymatic recycling of pos... |
| 29.02.2024 | CARBIOS et Landbell Group s’unissent pour accroître la circularité des déchets PET dans la première usine de biorecyclage | CARBIOS et Landbell Group s’unissent pour accroître la circularité des déchets PET dans la première usine de biorecyclage CARBIOS et Landbell Group signent un accord pour le développement et la mise en œuvre de solutions pour le tri, la pré... |
| 19.02.2024 | CARBIOS fédère les acteurs de la filière textile pour impulser la circularité du secteur en présence de M. Bruno Le Maire, Ministre de l’Economie, des Finances et de la Souveraineté industrielle et nu... | CARBIOS fédère les acteurs de la filière textile pour impulser la circularité du secteur en présence de M. Bruno Le Maire, Ministre de l’Economie, des Finances et de la Souveraineté industrielle et numérique
Clermont-Ferrand (France), le 19... |
| 19.02.2024 | CARBIOS rallies players to promote textile circularity sector in the presence of M. Bruno Le Maire, Minister of Economy, Finance and Industrial and Digital Sovereignty | CARBIOS rallies players to promote textile circularity sector in the presence of M. Bruno Le Maire, Minister of Economy, Finance and Industrial and Digital Sovereignty
Clermont-Ferrand, France, 19 February 2024 (06.45am CET) CARBIOS (Eurone... |
| 06.02.2024 | TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care | MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financ... |
| 11.09.2023 | BioM presents Bavarian biotech companies and their innovative solutions at BIO-Europe in Munich | Europe's largest biotech partnering trade fair with attendance record
From 6 to 8 November, Bavarian biotechnology showed a strong presence at BIO-Europe in Munich. As the local host of the most important biotech partnering trade fair in E... |
| 20.07.2023 | Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis | Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local treatment
Mage Bio... |
| 27.04.2023 | Rentschler Biopharma Receives Worcester Business Journal 2023 Manufacturing Excellence Award | Company presented with Workforce Development Award, recognizing partnership with MassBioEd and WPI to train people for biotech manufacturing positions Company honored at Worcester Business Journal Manufacturing Summit and Excellence Awards ... |
| 24.03.2023 | Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round | March 23, 2023 |
| 17.03.2023 | TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023 | Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner... |
| 23.02.2023 | TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders | Montreal, Canada / Munich, Germany – 23 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the promotion of Dr. Valentina Agosto... |
| 22.02.2023 | Abivax Announces Successful Oversubscribed EUR 130M Cross-Over Financing at Market Price with Top-Tier US and European Biotech Investors | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
This f... |
| 21.02.2023 | Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ | Montréal, Québec, February 21, 2023 – Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a follow-on investment by TVM Capital Life Science (“TVM”) through its fund TVM Life Science Innovation I SCSp and ... |
| 14.02.2023 | Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO | Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA, miR-124
The presentation will b... |
| 13.02.2023 | BIO-Europe Spring(R) 2023 is Back In-Person and Setting Records as Europe’s Largest and Most International Biopharma Industry Gathering of the Spring | MUNICH, GERMANY / ACCESSWIRE / February 13, 2023 / The seventeenth annual BIO-Europe Spring®, premier springtime partnering conference, is back in-person and will be taking place March 20-22, 2023 in Basel, Switzerland. After being held dig... |
| 08.02.2023 | TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients | LAmAb Biologics to develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases
LAmAb Biologics is the 9th early-stage or product focused company (PFC) investment for TVM Life Scie... |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund
Recurv is developing novel taxane, RP-001, against solid tumors
RP-001 delivered in nano-emulsion formulation, focusing drug... |
| 05.01.2023 | Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action | The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases in proinflammatory cytokines and thu... |
| 14.12.2022 | Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference | Abivax's senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event from January 9-12 in San Francisco, US
PARIS, FRANCE / ACCESSWIRE / December 14, ... |
| 07.12.2022 | Rentschler implements innovative learning program in collaboration with MassBioEd and WPI | Program trains people returning to the workforce for biotech manufacturing positions
/EIN News/ -- LAUPHEIM, Germany and MILFORD, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manuf... |
| 26.10.2022 | Harro Höfliger and LEON collaborate to bring the innovative NANOus LNP-encapsulation device to market for rapid, large-scale prophylactic vaccine manufacturing | LEON and Harro Höfliger to build and commercialize LEON’s NANOus, a novel aseptic manufacturing device to facilitate commercial production of LNP-encapsulated genetic materials and other APIs
By enabling easy scale-up, PAT and GMP-complianc... |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine
Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases
Signals new phase for Adrestia’s portfolio of va... |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine
Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases
Signals new phase for Adrestia’s portfolio of va... |
| 25.10.2022 | avateramedical to present at ERUS meeting after successful completion of first live surgery at DRUS congress | First broadcast of a live surgery with the avatera system performing a radical prostatectomy during the DRUS meetingavateramedical’s CEO Greg Roche to present at the ERUS (EAU Robotic Urology Section) meeting on October 28thExpansion of ava... |
| 11.10.2022 | First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis | First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US
1,200 UC patients across 36 countries and 600 study centers will t... |
| 22.09.2022 | Spexis announces positive renal impairment clinical trial results with balixafortide | Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide than those previously investigatedAdditio... |
| 16.09.2022 | Aignostics Raises €14m Series A to Advance AI-powered Pathology | September 15, 2022 |
| 15.09.2022 | Aignostics Raises €14m Series A to Advance AI-powered Pathology | Oversubscribed financing round with top-tier life science investors, led by Wellington PartnersSpin-off from Charité – Universitätsmedizin Berlin developing sophisticated AI models to improve understanding, diagnosis and treatment of comple... |
| 06.09.2022 | Spexis provides business update and announces financial results for the first half of 2022 | Ad hoc announcement pursuant to Art. 53 LR
Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals of trial sites
Enrollment of Phase 1 trial... |
| 31.08.2022 | Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September | ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss... |
| 18.08.2022 | Rentschler Biopharma appoints Mark Caswell as Vice President, Site Head for US Facility | LAUPHEIM, Germany and MILFORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Mark Caswel... |
| 16.08.2022 | Abivax Announces a Change in Its Governance | PARIS, FRANCE / ACCESSWIRE / August 16, 2022 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases,... |
| 28.07.2022 | Spexis provides business update | Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renally impaired... |
| 20.07.2022 | Spexis announces business update call to be held on July 28th | ALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday,... |
| 07.07.2022 | Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model | ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with doceta... |
| 13.06.2022 | Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP | Company hires Kassim Kolia, as Vice President, Business Development to grow cell and gene therapy business
Stevenage ATMP site projected to be client ready for process development in late 2022
STEVENAGE, United Kingdom and LAUPHEIM, Germany... |
| 10.06.2022 | Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting | Shareholders approved all proposed resolutions
PARIS, FRANCE / ACCESSWIRE / June 10, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system t... |
| 19.05.2022 | Spexis to Present at H.C. Wainwright Global Investment Conference | ALLSCHWIL, Switzerland, May 19, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, in Miami Beach, FL, USA and virt... |
